Valuation: Arctic Bioscience

Market Cap 68.47M 7.16M 6.49M 6M 5.42M 10.21M 675M 10.57M 72.12M 28.6M 361M 26.88M 26.31M 1.15B P/E 2026 *
-2.85x
P/E 2027 * -
Enterprise Value 134M 14.07M 12.75M 11.79M 10.64M 20.05M 1.33B 20.75M 142M 56.16M 708M 52.79M 51.67M 2.25B EV / Sales 2026 *
2.32x
EV / Sales 2027 * -
Free-Float
45.02%
Yield 2026 *
-
Yield 2027 * -
1 day+3.67%
1 week+6.28%
Current month+15.45%
1 month+6.72%
3 months-15.33%
6 months-23.03%
Current year-22.56%
1 week 2.1
Extreme 2.1
2.67
1 month 2.05
Extreme 2.05
2.7
Current year 2.05
Extreme 2.05
3.67
1 year 2.05
Extreme 2.05
4.1
3 years 1.65
Extreme 1.65
16.8
5 years 1.65
Extreme 1.65
21.7
10 years 1.65
Extreme 1.65
32
Manager TitleAgeSince
Chief Executive Officer 60 01/01/2011
Chief Executive Officer 54 01/03/2022
Director of Finance/CFO 47 01/04/2022
Director TitleAgeSince
Chairman 68 01/12/2015
Director/Board Member 55 01/01/2015
Director/Board Member 46 01/01/2021
Date Insider Type Main position Quantity % Market Cap. Importance
24/04/23 Buy

Director

943,833 3.8641%
24/04/23 Buy

Director

943,833 3.8641%
23/02/23 Buy

Chief Technology Officer

11,500 0.0472%
Change 5-day change 1-year change 3-year change Capi.($)
+3.67%+6.28%-31.35%-70.05% 7.16M
+1.26%+6.61%+40.79%+136.32% 1,286B
+0.79%+3.45%+45.84%+93.52% 688B
+0.20%+1.28%+26.97%+113.70% 521B
-0.44%+3.69%+41.45%+68.91% 386B
+0.55%+0.70%+59.02%+44.62% 364B
-0.12%+0.74%+28.39%+58.54% 302B
+0.37%+0.37%+3.33%+37.27% 287B
-0.30%+1.14%+38.29%+72.46% 252B
+0.08%+0.71%+34.44%+124.95% 208B
Average +0.61%+2.50%+28.72%+68.02% 429B
Weighted average by Cap. +0.54%+3.26%+37.70%+96.50%

Financials

2026 *2027 *
Net sales 58M 6.07M 5.5M 5.09M 4.59M 8.65M 572M 8.95M 61.09M 24.22M 306M 22.77M 22.29M 970M -
Net income -24M -2.51M -2.28M -2.1M -1.9M -3.58M -237M -3.7M -25.28M -10.02M -126M -9.42M -9.22M -401M -
Net Debt 66M 6.9M 6.26M 5.79M 5.22M 9.84M 651M 10.19M 69.52M 27.56M 348M 25.91M 25.36M 1.1B -
Projected Income Statement - Annual - Arctic Bioscience
Logo Arctic Bioscience
Arctic Bioscience AS is a Norway-based biotech company developing and commercializing both pharmaceutical and nutraceutical products based on the properties of herring roe oil. Arctic Bioscience’s purpose is to provide people with autoimmune disorders an effective and healthy therapy based on marine membrane lipids. The Company is developing HRO350 - a novel investigational drug candidate. HRO350 is being developed for treatment of patients with mild-to-moderate psoriasis. The Company's product portfolio includes, among others, Romega, which is a producer of an omega-3 dietary supplement made from herring roe in a form of a capsule, as well as herring caviar oil and herring caviar protein offered to Business-to-Business (B2B) customers. Arctic Bioscience AS has three subsidiaries Arctic Nutrition AS, Romega AS and Arctic Biopharma AS.
Employees
19
Date Price Change Volume
13/11/26 NOK 2.540 +3.67% 100
12/11/26 NOK 2.450 +6.99% 5,374
11/11/26 NOK 2.290 -8.40% 64,969
10/11/26 NOK 2.500 -1.96% 12,730
09/11/26 NOK 2.550 +6.69% 800
Trader
-
Investor
-
Global
-
Quality
ESG MSCI
-
MarketScreener Ratings - Arctic Bioscience

Annual profits - Rate of surprise

Rate of surprise - EPS - Annual - Arctic Bioscience